A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18 F-FB-A20FMDV2 for Imaging the Integrin α v β 6

• Published in: Journal of nuclear medicine technology Vol. 46; no. 2; pp. 136 - 143
• Main Authors: Keat, Nicholas, Kenny, Julia, Chen, Keguan, Onega, Mayca, Garman, Nadia, Slack, Robert J, Parker, Christine A, Lumbers, R Thomas, Hallett, Will, Saleem, Azeem, Passchier, Jan, Lukey, Pauline T
• Format: Journal Article
• Language: English
• Published: United States 01-06-2018
• Subjects: Aged; Amino Acid Sequence; Antigens, Neoplasm - metabolism; Female; Fluorine Radioisotopes; Foot-and-Mouth Disease Virus; Humans; Integrins - metabolism; Male; Middle Aged; Peptide Fragments - adverse effects; Peptide Fragments - chemistry; Peptide Fragments - immunology; Peptide Fragments - pharmacokinetics; Positron-Emission Tomography - methods; Radiation Dosage; Radiometry; Safety; Tissue Distribution; Viral Proteins - chemistry; A20FMDV2; FTiH; integrin; αvβ6; PET
• ISSN: 0091-4916; 1535-5675
• DOI: 10.2967/jnmt.117.203547

The α
β
integrin is involved in the pathogenesis of cancer and fibrosis. A radiolabeled 20-amino-acid α
β
-binding peptide, derived from the foot and mouth virus (NAVPNLRGDLQVLAQKVART [A20FMDV2]), has been developed to image α
β
levels preclinically. This study was designed to translate these findings into a clinical PET imaging protocol to measure the expression of α
β
in humans.
Preclinical toxicology was undertaken, and a direct immunoassay was developed for 4-fluorobenzamide (FB)-A20FMDV2. Four healthy human subjects (2 male and 2 female) received a single microdose of
F-FB-A20FMDV2 followed by a multibed PET scan of the whole body over more than 3 h.
There were no findings in the preclinical toxicology assessments, and no anti-A20FMDV2 antibodies were detected before or after dosing with the PET ligand. The mean and SD of the administered mass of
F-FB-A20FMDV2 was 8.7 ± 4.4 μg (range, 2.7-13.0 μg). The mean administered activity was 124 ± 20 MBq (range, 98-145 MBq). There were no adverse or clinically detectable pharmacologic effects in any of the subjects. No significant changes in vital signs, laboratory study results, or electrocardiography results were observed. Uptake of radioactivity was observed in the thyroid, salivary glands, liver, stomach wall, spleen, kidneys, ureters, and bladder. Time-activity curves indicated that the highest activity was in the bladder content, followed by the kidneys, small intestine, stomach, liver, spleen, thyroid, and gallbladder. The largest component of the residence times was the voided urine, followed by muscle, bladder, and liver. Using the mean residence time over all subjects as input to OLINDA/EXM, the effective dose was determined to be 0.0217 mSv/MBq; using residence times from single subjects gave an SD of 0.0020 mSv/MBq from the mean. The critical organ was the urinary bladder, with an absorbed dose of 0.18 mGy/MBq.
F-FB-A20FMDV2 successfully passed toxicology criteria, showed no adverse effects in this first-in-humans study, and has an effective dose that enables multiple scans in a single subject.